What does 'research use only' actually mean?

What does a 'research use only' label look like?

On a diagnostic product, the US rule requires the words “For Research Use Only. Not for use in diagnostic procedures,” prominently placed on all of its labelling¹. A new drug shipped for lab work carries a longer caution: “Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans”².

A vial sold online may carry its own version. The FDA's August 2026 warning letter quotes one seller's labelling, which paired “research use only” with “not for human consumption”⁷. No version of the label tells you who made the vial or what is in it.

What do 'for in vitro use only' and 'laboratory use only' mean?

'For in vitro use only' means the product is meant for tests in the laboratory, outside the body²⁰. The US rule for new drugs shipped for that work adds a plain warning: “Not for use in humans”². 'Laboratory use only' points the same way: EU law leaves products for general laboratory use outside its rules for diagnostic tests, unless the maker intends them for diagnosis¹⁴.

An approved lab test reads differently again. US rules require a product meant for diagnosis to say “For In Vitro Diagnostic Use”¹. All of these phrases state what the maker says a product is for. None of them makes a product legal to sell for people, because US law judges a product by its intended use, shown by the seller's own words and how it is sold³.

What does 'not for human consumption' on a vial mean?

It means the seller says the product is not meant for people. The FDA does not take that line at face value when the rest of the sales pitch says the opposite⁷.

In an August 2026 warning letter, the FDA wrote that despite labelling that marketed the products for “research use only” and “not for human consumption,” evidence from the seller's website established that the products were intended to be drugs for human use⁷. The evidence was ordinary marketing copy: claims about metabolic and recovery effects, named conditions, and reconstitution water sold alongside the vials⁷.

Does the FDA review products labelled 'research use only'?

No. The FDA's 2013 guidance says research use only labelling must match the maker's intended use⁵, and the Federal Register notice announcing it described mislabelled products being used for diagnosis when their performance was unproven⁶.

So the label records that a product has not been through the review its end use would need. It does not record that any review took place.

Can a seller make a product legal by labelling it 'research use only'?

No. Under 21 CFR 201.128, intended use is shown by objective evidence, such as the seller's own statements, the design of the product and how it is advertised, and not by the label text alone³. The statutory definition agrees: an article is a drug if it is intended to affect the structure or any function of the body, or to treat or prevent disease⁴.

Import Alert 66-41 gives the FDA a second route at the border, allowing detention without physical examination of unapproved new drugs promoted in the United States⁸. Neither route turns on what the vial says.

Is there a lawful route for a peptide to reach a person without full approval?

There is one, and it runs through pharmacy compounding law. A bulk substance used in 503A compounding must meet any applicable USP or NF monograph and be made by an FDA-registered establishment⁹, and the FDA sorts nominated substances by whether it has found a significant safety risk¹⁰.

BPC-157 left the agency's safety risk list on 22 April 2026^11,21, and that did not by itself make it eligible for compounding²¹. The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026. It recommended six of seven peptides, among them BPC-157, TB-500 and MOTS-c, against the agency staff's written position^12,13,19. On 28 October 2026 HHS then published an interim policy. It says HHS does not intend to take enforcement action against licensed compounders of six named peptides who meet ten conditions. That lasts until the FDA decides each peptide in a final rule²¹. The policy is a promise about enforcement. It does not change the law. It requires an FDA-registered maker and a certificate of analysis, and a research use only label supplies neither²¹. What the policy says.

What does 'research use only' mean under EU law?

The EU splits the question the same way. Regulation (EU) 2017/746 leaves research use only products outside its rules for diagnostic devices, unless the maker specifically intends them for diagnostic examination^14,15.

For medicines, Directive 2001/83/EC defines a medicinal product by what it is meant to do to the body, and Article 6(1) bars any medicinal product from a Member State's market without a marketing authorisation¹⁶. As in the United States, the label narrows an exemption. It gives no permission to sell a compound for people to use on themselves.

Does the label tell you anything about what is actually in the vial?

No. A 2024 analysis in the Journal of Medical Internet Research tested semaglutide bought from online sellers without a prescription, the same unregulated supply chain that research use only peptides move through. Every sample was assessed as substandard or falsified. Measured content ran 28.56 to 38.69 percent above the labelled amount, purity fell between 7.7 and 14.37 percent against a claimed 99 percent, and endotoxin was present in all samples tested¹⁸.

That study covered one compound, so read it as evidence about the supply chain rather than about any specific peptide. No peer reviewed purity or content analysis specific to BPC-157 or TB-500 was located. That absence is part of the answer: the label guarantees nothing, and no public dataset fills the gap.

Does 'research use only' mean anything in competitive sport?

Yes, and here the answer is blunt. The WADA Prohibited List in force from 1 January 2026 includes category S0, non-approved substances, covering any pharmacological substance with no current approval by a governmental regulatory health authority for human therapeutic use. Substances in S0 are prohibited at all times, and BPC-157 is named as an example¹⁷.

For an athlete under the WADA code, the absence of regulatory approval is itself the basis for the ban. The research label creates no grey area at all.

What would change this answer

A final FDA rule on any of the six peptides, which would end the interim policy for that peptide. HHS narrowing or withdrawing the policy. A guidance document addressing research use only labelling on peptides sold to consumers rather than on diagnostic reagents. A published purity analysis of the specific peptides most often sold under this label. An update to the WADA S0 category. Any one of these would require parts of this answer to be rewritten.